Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors. Truist Securities increased its price target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $230 from $220 on January 12, preserving a Buy rating on the company. The rise follows practice-changing results from the HERIZON-GEA trial, which Truist used to justify adjusting its Ziihera estimations higher.

In order to get a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy with priority review, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) executives intends to file a supplemental Biologics License Application (sBLA) in the initial half of 2026.

After clearance based on clinical data, Truist Securities anticipates strong commercial adoption, probable adoption in NCCN guidelines, over 90% prescriber crossover between GEA and biliary tract cancer (BTC), and compatibility of PD-1 inhibitor selection.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

While we acknowledge the potential of JAZZ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JAZZ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.